No Data
Xintian Pharmaceutical (002873.SZ): Net profit of 15.571,600 yuan in the first quarter decreased by 37.94% year-on-year
Gelonghui, April 26 | Xintian Pharmaceutical (002873.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 177 million yuan, down 15.06% year on year; net profit attributable to shareholders of listed companies was 15.571,600 yuan, down 37.94% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 147.152 million yuan, down 38.53% year on year; basic earnings per share were 0.0673 yuan.
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms a
Tianfeng Securities released a research report on April 18 stating that it gave Xintian Pharmaceutical (002873.SZ) an increase in holdings rating. The main reasons for the rating include: 1) revenue pressure on core products; 2) marketing system reforms are showing initial results, and costs have been optimized; 3) epitaxial expansion is expected to form a “traditional Chinese medicine+chemical medicine” dual-track pattern. (Mainichi Keizai Shimbun)
Xintian Pharmaceutical (002873): Short-term performance is under pressure, marketing system reform is beginning to bear fruit
Incident: On April 12, 2024, Xintian Pharmaceutical disclosed its 2023 annual report. In 2023, the company achieved operating income of 954 million yuan, -12.29% year-on-year; achieved net profit of 81 million yuan to mother
Xintian Pharmaceutical (002873.SZ): Strategically invested in Huilun Pharmaceutical, the current shareholding ratio is 14.88%
Gelonghui, April 17 | Xintian Pharmaceutical (002873.SZ) said on the investor interactive platform that the company's strategic investment in Huilun Pharmaceutical currently has a shareholding ratio of 14.88%. According to relevant accounting policy regulations, it has not yet been included in the scope of the company's consolidated statements, and changes in its operating performance will not have a significant impact on the company's 2023 net profit and other indicators. According to a thorough understanding of the business situation of Huilun Pharmaceutical Company, it is a high-tech enterprise dedicated to R&D and technical services for small molecule innovative drugs and generic drugs. The industrialization and commercialization process of its chemical products has been steady, and its business has grown rapidly in the past three years. 2
Xintian Pharmaceutical (002873): Performance under phased pressure continues to consolidate core competitiveness and unleash growth potential
The company's performance is under phased pressure, and the adjustment cost investment focuses on long-term development. The company released its 2023 annual report: in 2023, the company achieved operating income of 954 million yuan (-12.29%) and net profit of 81 million yuan to mother (-
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is
China Post Securities released a research report on April 12 stating that it gave Xintian Pharmaceutical (002873.SZ) a purchase rating. The main reasons for the rating include: 1) the company's performance is under phased pressure, and cost investment is being adjusted to focus on long-term development; 2) channel expansion is being further promoted, production capacity is continuously strengthened, and core competitiveness is continuously consolidated; 3) the intention to control Huilun Pharmaceutical through equity acquisition to deepen the small molecule chemical business layout, which is expected to enhance the company's performance. (Mainichi Keizai Shimbun)